Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study | Global News Avenue

Novo Nordisk’s (NGOs) After new data was released, U.S. listed stocks fell Phase III clinical trial Its internal weight loss medication genitals.

In the second phase of the combined drug study, the average weight loss of about 1,200 patients in the study accounted for 15.7% of their weight after 68 weeks, compared with 3.1% of those receiving the placebo.

Ozempic and Wegovy’s manufacturer’s research follows the first phase 3 trial The results of anger in December This reduced the patient by 22.7% of his body weight. After this study, 17% shared Bloomberg The result is reportedly Novo Nordisk’s goal is to lose 25% of weight with the new drug.

Novo Nordisk still plans to conduct two phase 3 trials for Cagrisema and said it is still expected to submit the drug for regulatory approval in the first quarter of 2026 on Monday.

Shares of Danish drugmakers fell more than 7% on Monday morning. They’ve been following other recently Test results and Stable sales Among the current weight loss medications, it has dropped by 39% in the past year.